文献速递泌尿男性生殖肿瘤

纳武利尤单抗联合多西他赛治疗化疗初治转移性去势抵抗性前列腺癌:II期CheckMate 9KD试验结果

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
PubMed 文献 · Eur J Cancer · 2021-11-18

这项非随机、多队列、全球II期CheckMate 9KD试验纳入84例化疗初治转移性去势抵抗性前列腺癌患者,接受纳武利尤单抗联合多西他赛及泼尼松治疗。确认的客观缓解率为40.0%,前列腺特异性抗原应答率(PSA50-RR)为46.9%,中位影像学无进展生存期9.0个月,中位总生存期18.2个月。结论认为该联合方案具有临床活性,安全性与其各单药成分一致。

要点

  • 确认的客观缓解率为40.0%(95%CI 25.7-55.7),确认的PSA50-RR为46.9%(95%CI 35.7-58.3)。
  • 中位影像学无进展生存期为9.0个月(95%CI 8.0-11.6),中位总生存期为18.2个月(95%CI 14.6-20.7)。
  • 最常见的任何级别治疗相关不良事件为疲乏(39.3%),最常见的3-4级为中性粒细胞减少(16.7%)。

核心结论

  • 纳武利尤单抗联合多西他赛在化疗初治转移性去势抵抗性前列腺癌患者中具有临床活性。
  • 安全性与其各单药成分一致。
  • 结果支持在正在进行的III期CheckMate 7DX试验中进一步研究。

研究设计与样本

  • 非随机、多队列、全球II期CheckMate 9KD试验,纳入84例化疗初治转移性去势抵抗性前列腺癌患者。
  • 患者需持续雄激素剥夺治疗且既往接受≤2种新型激素治疗。
  • 治疗方案为纳武利尤单抗360 mg联合多西他赛75 mg/m2每3周一次,联合泼尼松5 mg每日两次(≤10个周期),随后纳武利尤单抗480 mg每4周一次(≤2年)。
  • 共同主要终点为客观缓解率和前列腺特异性抗原应答率(PSA50-RR,较基线下降≥50%)。

主要发现

  • 确认的客观缓解率为40.0%(95%CI 25.7-55.7),确认的PSA50-RR为46.9%(95%CI 35.7-58.3)。
  • 中位影像学无进展生存期为9.0个月(95%CI 8.0-11.6),中位总生存期为18.2个月(95%CI 14.6-20.7)。
  • 有既往新型激素治疗史亚组与无既往新型激素治疗史亚组相比:客观缓解率38.7% vs 42.9%,PSA50-RR 39.6% vs 60.7%,中位影像学无进展生存期8.5 vs 12.0个月,中位总生存期16.2个月 vs 未达到。
  • 同源重组缺陷状态或肿瘤突变负荷似乎不影响疗效。
  • 最常见的任何级别治疗相关不良事件为疲乏(39.3%),最常见的3-4级治疗相关不良事件为中性粒细胞减少(16.7%)。

关键数值与推荐

  • 确认的客观缓解率40.0%(95%CI 25.7-55.7)。
  • 确认的PSA50-RR 46.9%(95%CI 35.7-58.3)。
  • 中位影像学无进展生存期9.0个月(95%CI 8.0-11.6),中位总生存期18.2个月(95%CI 14.6-20.7)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论认为纳武利尤单抗联合多西他赛在化疗初治转移性去势抵抗性前列腺癌患者中具有临床活性,安全性与其各单药成分一致。
  • 作者认为结果支持在正在进行的III期CheckMate 7DX试验中进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC). METHODS: In the non-randomised, multicohort, global phase II CheckMate 9KD trial, 84 patients with chemotherapy-naive mCRPC, ongoing androgen deprivation therapy and ≤2 prior novel hormonal therapies (NHTs) received nivolumab 360 mg and docetaxel 75 mg/m2 every 3 weeks with prednisone 5 mg twice daily (≤10 cycles) and then nivolumab 480 mg every 4 weeks (≤2 years). The co-primary end-points were objective response rate (ORR) and prostate-specific antigen response rate (PSA50-RR; ≥50% decrease from baseline). RESULTS: The confirmed ORR (95% confidence interval [CI]) was 40.0% (25.7-55.7), and the confirmed PSA50-RR (95% CI) was 46.9% (35.7-58.3). The median (95% CI) radiographic progression-free survival (rPFS) and overall survival (OS) were 9.0 (8.0-11.6) and 18.2 (14.6-20.7) months, respectively. In subpopulations with versus without prior NHT, the ORR was 38.7% versus 42.9%, the PSA50-RR was 39.6% versus 60.7%, the median rPFS was 8.5 versus 12.0 months and the median OS was 16.2 months versus not reached. Homologous recombination deficiency status or tumour mutational burden did not appear to impact efficacy. The most common any-grade and grade 3-4 treatment-related adverse events were fatigue (39.3%) and neutropenia (16.7%), respectively. Three treatment-related deaths occurred (1 pneumonitis related to nivolumab; 2 pneumonias related to docetaxel). CONCLUSIONS: Nivolumab plus docetaxel has clinical activity in patients with chemotherapy-naïve mCRPC. Safety was consistent with the individual components. These results support further investigation in the ongoing phase III CheckMate 7DX trial. CLINICALTRIALS. GOV REGISTRATION: NCT03338790.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fizazi K, González Mella P, Castellano D, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2021. PMID: 34802864. doi:10.1016/j.ejca.2021.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。